SALT LAKE CITY, Aug. 22, 2017 (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (NASDAQ:COOL) today announced the appointment of Jennifer Burdman as its Chief Intellectual Property Officer and Deputy General Counsel.  Ms. Burdman joins PolarityTE from the international law firm of King & Spalding LLP, where she was a partner in the Washington, D.C. office specializing in intellectual property procurement, protection, and enforcement.  Ms. Burdman has a background in biochemistry and molecular biology, and has specific experience in the tissue engineering field. 

“We believe our platform technology represents a true paradigm shift in regenerative medicine, and we recognize that our intellectual property is the lifeblood of our company,” said Denver Lough, MD, PhD, Chairman, Chief Executive Officer, and Chief Scientific Officer of PolarityTE™. “Our goal is to continue to develop, protect, and enforce our intellectual property in the most effective and comprehensive way we can.  We have enjoyed working with Ms. Burdman and King & Spalding to execute our intellectual property strategy to date, and we are thrilled to bring her in house so that she can devote all of her time and expertise to PolarityTE.  Ms. Burdman's experience will be invaluable as we not only continue to develop our intellectual property and patent portfolio, but also as we explore collaborative opportunities with strategic partners.” 

“Working with the PolarityTE team over the past few months, I have been incredibly impressed with the innovative technology they have developed and their commitment to applying that technology to transform regenerative medicine,” commented Ms. Burdman. “I'm looking forward to joining them in those pursuits.”

About Jennifer Burdman, Esq.

Jennifer Burdman, Esq. is an intellectual property attorney specializing in IP procurement, protection, and enforcement. Ms. Burdman develops IP strategies and advises on their implementation in the business setting, including licensing deals and other strategic collaborations.  An experienced trial lawyer, she has successfully represented clients at the trial and appellate levels in complex, high-stakes litigations in patent infringement, trade secret misappropriation, and contractual matters involving IP rights.  In 2016, Ms. Burdman was profiled as a “Law360 Rising Star” and named to their 2016 Intellectual Property Editorial Advisory Board.  She was also named to Benchmark Litigation’s inaugural Under 40 Hot List in 2016, and again in 2017. The National Law Journal named her a 2015 “Rising Star" in Washington, D.C. 

Ms. Burdman’s thought leadership in the intellectual property field has been featured in the Bloomberg BNA Daily Report for Executives and the Intellectual Property & Technology Law Journal, among others. Noteworthy cases include a jury verdict of patent infringement related to the preservation of soft tissue grafts resulting in over $34 million in damages, a jury verdict of willful misappropriation of trade secrets relating to Kevlar with damages of over $900 million, and the successful defense of The Regents of the University of California against a patent licensee seeking expanded rights relating to its sponsored research and license agreements relating to compounds for the treatment of prostate cancer. 

Ms. Burdman graduated from Dartmouth College with an A.B. in biochemistry and molecular biology and received her J.D. from Fordham University School of Law.

About the PolarityTE™ Platform

The PolarityTE™ investigational platform is being developed to simplify regeneration and allow tissue and cellular elements to function naturally. Using our revolutionary platform, we seek to utilize cell and tissue polarity to create a spectrum of uniquely functional tissues in a way that mirrors the natural development of the human body. Our goal is to apply the platform across all cells, tissues and composite structures, transforming regenerative medicine into what has been envisioned since its inception.

About PolarityTE™
PolarityTE™, Inc. is a regenerative medicine company positioned to be the first to successfully regenerate human skin. The Company's novel regenerative medicine and tissue engineering platform was developed and patented by chairman and chief executive officer, Denver Lough M.D., Ph.D. This radical and proprietary technology employs a patient's own cells for the healing of full-thickness, functionally-polarized tissues. If clinically successful, the PolarityTE™ platform will provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The PolarityTE™ platform leverages natural and biologically-sound principles which are readily adaptable to a wide spectrum of organ and tissue systems. This revolutionary technology, paired with the Company's world-renowned clinical advisory board, position PolarityTE™ to drastically change the field and future of translational regenerative medicine. More information can be found online at

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.


Scott Santiamo
(718) 344-5843

David Schull
(858) 717-2310